🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

An Overview of the Antioxidant, Anti-inflammatory, and Anticancer Effects of Statins.

PMID: 41588902 · DOI: 10.2174/0118715206377993251115050803 · Anti-cancer agents in medicinal chemistry, 2026 · Fatemeh Zarei, Zahra Salimi, Motahareh Zeinivand, Nastaran Zamani, Reza Bahrani
📄 Abstract

Statins are a class of cholesterol-lowering agents widely used in clinical practice to reduce plasma levels of low-density lipoprotein cholesterol in hyperlipidemic patients. Beyond their lipidlowering roles, statins exhibit several additional effects. In the current review, we searched PubMed, ScienceDirect, and Google Scholar databases using the keywords "Statins," "HMG-CoA reductase inhibitors," "Anti-inflammatory," "Antioxidant," and "Anticancer" to provide an overview of the effects of statins. Articles published on these topics between 1990 and 2025 were included. The retrieved records were imported into EndNote, and duplicates were removed. Multiple potential therapeutic benefits of statins have been described, including suppression of apoptosis, antioxidant, anti-inflammatory and anticancer effects, immunomodulation and neuroprotection. NADPH oxidases (NOX) play a crucial role in the development of various diseases through excessive production of reactive oxygen species (ROS) and the creation of oxidative stress conditions. Stimulation of BDNF/Nrf2, inhibition of NOX pathways, and reduction of intracellular ROS via enhanced antioxidant activity represent possible mechanisms through which statins exert their effects. Interestingly, ROS and inflammatory cytokines activate nuclear factor kappa B (NF-κB), a critical factor in the development of malignant tumors, which induces the expression of genes involved in cell proliferation and carcinogenesis. Furthermore, statins inhibit NF-κB activity, a key transcriptional regulator in inflammatory responses. Clinical evidence suggests that statins may reduce the risk of various cancers and disease recurrence due to their anti-inflammatory and antioxidant properties. These findings form the basis for new therapeutic avenues in cancer treatment, potentially offering a more promising strategy than statin monotherapy.

Confidence: 0.34 · 18 полей извлечено
Идентификация (6 полей)
Target
HMG-CoA reductase
0.90
Alt. target
HMGCR
0.80
Protein family
oxidoreductase
0.70
Functional class
enzyme
0.80
Subcellular loc.
endoplasmic reticulum membrane
0.70
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
Inhibition of HMG-CoA reductase; inhibition of NOX pathways; stimulation of BDNF/Nrf2; reduction of intracellular ROS; inhibition of NF-κB activity
0.90
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
Anti-inflammatory; inhibition of NF-κB activity
0.90
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
Suppression of apoptosis
0.80
Adipocyte fibrosis
0.00
Upstream (biochem)
NADPH oxidases (NOX); reactive oxygen species (ROS); inflammatory cytokines
0.80
Upstream (physiol)
0.00
Downstream (biochem)
BDNF/Nrf2 pathway; NF-κB; genes involved in cell proliferation and carcinogenesis
0.80
Downstream (physiol)
0.00
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
endometrial-endometriotic stromal cells treated with atorvastatin and lipopolysaccharide
0.90
In vivo
0.00
In silico
0.00
Genetic association
Mendelian randomization study in UK Biobank evaluating statins and cancer risk; Mendelian randomization study evaluating cholesterol lowering and head and neck cancer risk
0.90
Ex vivo
0.00
Animal model
apolipoprotein E-deficient mice
0.90
Diet/model
0.00
Клиника (11 полей)
Drug
Statins
1.00
Indication
Hyperlipidemia (to reduce plasma levels of low-density lipoprotein cholesterol)
1.00
Patient subgroups
Hyperlipidemic patients
1.00
Safety concerns
0.00
Off-target
Antioxidant, anti-inflammatory, anticancer, immunomodulation, neuroprotection
0.90
Trial stage
0.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
True
1.00